Back to Search Start Over

Transanal minimally invasive surgery (TAMIS) versus endoscopic submucosal dissection (ESD) for resection of non-pedunculated rectal lesions (TRIASSIC study): study protocol of a European multicenter randomised controlled trial.

Authors :
Dekkers N
Boonstra JJ
Moons LMG
Hompes R
Bastiaansen BA
Tuynman JB
Koch AD
Weusten BLAM
Pronk A
Neijenhuis PA
Westerterp M
van den Hout WB
Langers AMJ
van der Kraan J
Alkhalaf A
Lai JYL
Ter Borg F
Fabry H
Halet E
Schwartz MP
Nagengast WB
Straathof JWA
Ten Hove RWR
Oterdoom LH
Hoff C
Belt EJT
Zimmerman DDE
Hadithi M
Morreau H
de Cuba EMV
Leijtens JWA
Vasen HFA
van Leerdam ME
de Graaf EJR
Doornebosch PG
Hardwick JCH
Source :
BMC gastroenterology [BMC Gastroenterol] 2020 Jul 13; Vol. 20 (1), pp. 225. Date of Electronic Publication: 2020 Jul 13.
Publication Year :
2020

Abstract

Background: In the recent years two innovative approaches have become available for minimally invasive en bloc resections of large non-pedunculated rectal lesions (polyps and early cancers). One is Transanal Minimally Invasive Surgery (TAMIS), the other is Endoscopic Submucosal Dissection (ESD). Both techniques are standard of care, but a direct randomised comparison is lacking. The choice between either of these procedures is dependent on local expertise or availability rather than evidence-based. The European Society for Endoscopy has recommended that a comparison between ESD and local surgical resection is needed to guide decision making for the optimal approach for the removal of large rectal lesions in Western countries. The aim of this study is to directly compare both procedures in a randomised setting with regard to effectiveness, safety and perceived patient burden.<br />Methods: Multicenter randomised trial in 15 hospitals in the Netherlands. Patients with non-pedunculated lesions > 2 cm, where the bulk of the lesion is below 15 cm from the anal verge, will be randomised between either a TAMIS or an ESD procedure. Lesions judged to be deeply invasive by an expert panel will be excluded. The primary endpoint is the cumulative local recurrence rate at follow-up rectoscopy at 12 months. Secondary endpoints are: 1) Radical (R0-) resection rate; 2) Perceived burden and quality of life; 3) Cost effectiveness at 12 months; 4) Surgical referral rate at 12 months; 5) Complication rate; 6) Local recurrence rate at 6 months. For this non-inferiority trial, the total sample size of 198 is based on an expected local recurrence rate of 3% in the ESD group, 6% in the TAMIS group and considering a difference of less than 6% to be non-inferior.<br />Discussion: This is the first European randomised controlled trial comparing the effectiveness and safety of TAMIS and ESD for the en bloc resection of large non-pedunculated rectal lesions. This is important as the detection rate of these adenomas is expected to further increase with the introduction of colorectal screening programs throughout Europe. This study will therefore support an optimal use of healthcare resources in the future.<br />Trial Registration: Netherlands Trial Register, NL7083 , 06 July 2018.

Details

Language :
English
ISSN :
1471-230X
Volume :
20
Issue :
1
Database :
MEDLINE
Journal :
BMC gastroenterology
Publication Type :
Academic Journal
Accession number :
32660488
Full Text :
https://doi.org/10.1186/s12876-020-01367-z